Absence of vaccine-enhanced RSV disease and changes in pulmonary dendritic cells with adenovirus-based RSV vaccine Academic Article uri icon


MeSH Major

  • Dendritic Cells
  • Lung
  • Respiratory Syncytial Virus Infections
  • Respiratory Syncytial Virus Vaccines
  • Viral Fusion Proteins


  • The development of a vaccine against respiratory syncytial virus (RSV) has been hampered by the risk for vaccine-enhanced RSV pulmonary disease induced by immunization with formalin-inactivated RSV (FIRSV). This study focuses on the evaluation of vaccine-enhanced pulmonary disease following immunization with AdF.RGD, an integrin-targeted adenovirus vector that expresses the RSV F protein and includes an RGD (Arg-Gly-Asp) motif. Immunization of BALB/c mice with AdF.RGD, resulted in anti-RSV protective immunity and induced increased RSV-specific IFN-γ T cell responses compared to FIRSV. RSV infection 5 wk after immunization with FIRSV induced pulmonary inflammatory responses in the lung, that was not observed with AdF.RGD. Additionally, In the FIRSV-immunized mice following infection with RSV, pulmonary DC increased and Tregs decreased. This suggests that distinct responses of pulmonary DC and Tregs are a features of vaccine-enhanced RSV disease and that immunization with an RGD-modified Ad vaccine does not trigger vaccine-enhanced disease.

publication date

  • August 2, 2011



  • Academic Article



  • eng

PubMed Central ID

  • PMC3166937

Digital Object Identifier (DOI)

  • 10.1186/1743-422X-8-375

PubMed ID

  • 21801372

Additional Document Info

start page

  • 375


  • 8